Kang SC, et al. Immunosuppression in IgA nephropathy

KJIM

Supplementary Table 1. Baseline characteristics of patients with biopsy-proven immunoglobulin A nephropathy who underwent immunosuppressive therapy (at the time of kidney biopsy)

Variable	Total (n = 127)	Tertiles of proteinuria reduction after immunosuppressive therapy			p value
		Ter1 (n = 43)	Ter2 (n = 42)	Ter3 (n = 42)	
Demographic data					
Proteinuria, g/gCr	1.8 (1.2–3.3)	3.8 (2.0–5.1)	1.5 (1.2–1.9)	1.6 (0.8–2.3)	< 0.001
Age at biopsy, yr	39.6 ± 11.3	38.3 ± 9.9	39.7 ± 10.9	41.0 ± 12.9	0.54
Female sex	79 (62.2)	34 (79.1)	22 (52.4)	23 (54.8)	0.019
BMI, kg/m²	23.4 (21.3–26.4)	23.3 (21.1–26.9)	24.0 (22.4–26.9)	23.1 (20.6–25.0)	0.16
SBP, mmHg	121.2 ± 14.6	123.9 ± 20.5	120.9 ± 11.3	118.9 ± 9.4	0.34
DBP, mmHg	76.4 ± 9.9	78.0 ± 11.0	77.3 ± 9.2	74.1 ± 9.2	0.19
Laboratory parameters					
BUN, mg/dL	15.7 (13.0–18.5)	13.9 (12.4–17.3)	16.5 (13.0–19.8)	16.7 (14.9–19.1)	0.043
Creatinine, mg/dL	1.0 (0.8–1.3)	0.9 (0.6–1.2)	1.1 (0.8–1.4)	1.1 (0.9–1.3)	0.029
eGFR, mL/min/1.73 m²	79.3 (61.2–103.3)	85.2 (66.3–109.7)	73.3 (58.2–99.3)	76.0 (64.4–93.8)	0.18
Hemoglobin, g/dL	12.9 ± 1.8	12.9 ± 1.6	13.2 ± 1.9	12.6 ± 1.8	0.28
Calcium, mg/dL	8.9 (8.6–9.3)	8.8 (8.5–9.1)	9.1 (8.6–9.3)	9.0 (8.7–9.3)	0.052
Inorganic phosphorus, mg/dL	3.7 ± 0.6	3.7 ± 0.5	3.6 ± 0.6	3.8 ± 0.6	0.31
Uric acid, mg/dL	5.9 (4.7–6.9)	5.3 (4.4–6.7)	6.1 (5.1–7.1)	6.4 (5.0–7.0)	0.098
Total protein, g/dL	6.4 (6.1–6.9)	6.3 (5.7–6.8)	6.6 (6.2–7.0)	6.5 (6.1–7.0)	0.084
Albumin, g/dL	3.8 (3.5–4.1)	3.6 (3.2–4.0)	3.9 (3.7–4.2)	3.8 (3.6–4.2)	0.002
Total cholesterol, mg/dL	201.0 (174.0–235.0)	221.0 (201.0–270.0)	192.5 (178.0–214.0)	186.0 (164.0–223.0)	< 0.001
HDL-C, mg/dL	48.5 (40.0–61.0)	51.5 (41.5–61.5)	41.0 (40.0–57.0)	53.0 (41.0–64.0)	0.38
LDL-C, mg/dL	121.0 (106.0–150.0)	126.0 (116.0–181.0)	110.5 (93.0–142.0)	125.0 (110.0–135.0)	0.11
Triglyceride, mg/dL	140.0 (93.0–219.0)	148.5 (108.0–220.0)	186.0 (115.0–244.0)	118.0 (76.0–148.0)	0.053
Na, mmol/L	140.7 ± 1.9	140.1 ± 2.1	141.0 ± 2.0	140.8 ± 1.6	0.088
K, mmol/L	4.3 ± 0.4	4.3 ± 0.4	4.3 ± 0.4	4.3 ± 0.4	0.57
Cl, mmol/L	104.3 ± 2.3	104.4 ± 2.3	104.1 ± 2.2	104.5 ± 2.2	0.77
tCO2, mmol/L	25.7 ± 2.3	25.6 ± 2.3	25.8 ± 2.3	25.7 ± 2.4	0.95
Comorbidities					
HTN	104 (81.9)	35 (81.4)	33 (78.6)	36 (85.7)	0.69
DM	14 (11.0)	3 (7.0)	5 (11.9)	6 (14.3)	0.53
CVD	4 (3.1)	0	2 (4.8)	2 (4.8)	0.39
CHD	4 (3.1)	2 (4.7)	0	2 (4.8)	0.54
Medication history					
ACE inhibitor	5 (3.9)	0	2 (4.8)	3 (7.1)	0.23
ARB	78 (61.4)	20 (46.5)	29 (69.0)	29 (69.0)	0.047
Spironolactone	6 (4.7)	3 (7.0)	1 (2.4)	2 (4.8)	0.87
Statin	30 (23.6)	11 (25.6)	7 (16.7)	12 (28.6)	0.41

Values are presented as median (interquartile range), mean±standard deviation, or number (%).

Ter1, first tertile; Ter2, second tertile; Ter3, third tertile; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HTN, hypertension; DM, diabetes mellitus; CVD, cerebrovascular disease; CHD, coronary heart disease; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.